NCT05083585View on ClinicalTrials.gov

A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old

PHASE3CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

October 8, 2021

Primary Completion Date

March 7, 2022

Study Completion Date

September 22, 2022

Conditions
Respiratory Syncytial Virus Prevention
Interventions
BIOLOGICAL

Ad26.RSV.preF-based vaccine

Ad26.RSV.preF-based vaccine will be administered as a single intramuscular injection.

Trial Locations (9)

32127

Progressive Medical Research, Port Orange

32934

Optimal Research, Melbourne

33126

Pharmax Research Clinic Inc, Miami

33173

Research Institute of South Florida Inc, Miami

33803

Accel Research Sites, Lakeland

45219

Meridian Clinical Research, LLC, Cincinnati

78229

Tekton Research Inc., San Antonio

92103

Artemis Institute for Clinical Research, San Diego

92108

Optimal Research, San Diego

All Listed Sponsors
lead

Janssen Vaccines & Prevention B.V.

INDUSTRY

NCT05083585 - A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old | Biotech Hunter | Biotech Hunter